Cell line development plays a pivotal role in the manufacturing of therapeutic proteins, vaccines and other biologics.

Q4 2024 Earnings Call Transcript February 6, 2025 IQVIA Holdings Inc. beats earnings expectations. Reported EPS is $3.12, ...

Maze Therapeutics (MAZE) announced the first patient has been dosed in the company’s Phase 2 clinical trial, the HORIZON Study, of MZE829 in ...

AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim d ...

We are excited to announce the initiation of our HORIZON Study for MZE829, a Phase 2 clinical trial with a novel, potential new medicine that could disrupt current treatment for AKD,” said Harold ...

Within the open-label basket trial, patients with two copies of one of two high-risk APOL1 gene variants will receive MZE829.

An oft-repeated message is that primary aldosteronism is not rare; it is quite common. An equally urgent message is that ...